CORRECTION
Pfizer Licenses Out Compounds to Research Supply Company
The Big Pharma company has licensed a range of compounds to molecule research tools company Abcam to be made available for sale to pre-clinical researchers.
Archives for June 18, 2013
Wuxi to Help Develop, Manufacture ADC Candidate in China
Ambrx and Zhejiang Medicine have selected Wuxi to accelerate the development of a potential ADC (antibody drug conjugate) targeting Her2-positive breast cancer.
Eisai to Expand it's EMEA Packaging Capacity with New UK Plant
Eisai has announced plans to expand its global packaging capabilities with a £8m ($12.5m) facility in the UK.
AMRI's Burlington Plant Given Controlled Substance Boost from DEA
The DEA has approved AMRI’s Burlington facility to work with Schedule 2 controlled substances, placing it in a competitive position to win contract manufacturing bids, the company says.
Pfizer Selects South African Trial Sites for Partnership Program
Pfizer has chosen three of Synexus' clinical research centres in South Africa to be a part of its 100-site INSPIRE programme based on the sites’ experience and audit history.
Sanofi Proposes London Site as Science-Park as Manufacturing Ends
Sanofi has ended production at a historic London facility and says it plans to turn the site into a dedicated science park.
EU Risks Drug Shortages If API Import Regs Not Waived for US Says SOCMA
Europe could face drug shortages if the US is not granted exemption from new API import requirements, according to a US chemical industry trade association.
It Had To Be Yew? Not So Says Phyton With New Docetaxel CEP
Phyton Biotech has received European approval for a version the cancer drug API docetaxel whose production does not rely on the scarce yew tree extract used in traditional manufacturing methods.